Summary Binding of the cytostatic drug carboplatin to DNA was studied in solution, in RIF-I and CHO cell lines and in human buccal cells after in vitro or in situ drug exposure. Results were compared with DNA adduction by cisplatin. The rate of binding in solution, determined by atomic absorption spectroscopy, was 35 times lower for carboplatin than for cisplatin. Adduct formation in cells in vitro was determined in a quantitative immunostaining assay. Staining intensities after carboplatin treatment were at least 29 times lower than after an equimolar dose of cisplatin. For RIF-I and CHO cells, maximum levels of carboplatin-induced DNA modification were obtained 24 h after treatment; these levels correlated with cell killing. Adduct-specific staining in buccal cells from two carboplatin-treated patients increased 5-7 fold between 0 and 14 h after infusion, reaching a maximum at 10-14 h. This strongly contrasts with buccal cells from a cisplatin-treated patient, in which the adduct-specific staining signal increased by only 23% between 0 and 6 h after infusion, and then declined. This difference in the rate of adduct formation in vivo is consistent with the in vitro data.
recognised carboplatin-DNA adducts in a competitive ELISA and in a quantitative immunocytochemical peroxidase assay (Terheggen et al., 1988 .
Little is known on the formation of carboplatin-DNA adducts in cells or patients. Such knowledge might eventually contribute to the optimisation of patient anti-cancer treatment. We have therefore studied the binding of carboplatin to DNA in cultured cells and in buccal mucosa cells from carboplatin-treated cancer patients. The results were compared with adduct formation in DNA in solution and with the cytotoxic effects of carboplatin in vitro.
Materials and methods

DNA adduct formation in solution
One 1tmol calf thymus DNA-P in phosphate-buffer (0.2 mM Na2HPO4, 0.8 mM NaH2PO4, 3 mM NaCI; pH 7.4), pretreated with DNase S, (816 units mg-' DNA; Sigma, St. Louis, MO) , was incubated with 0.4 tLmol carboplatin (Carboplatin, Bristol-Myers, Weesp, The Netherlands) or 60 nmol cisDDP (Platinol, Bristol-Myers) for 0-72 h at 37°C in a volume of 1 ml. After 3-72 h, DNA was precipitated with ethanol overnight at -20°C, washed twice with 70% aqueous ethanol to remove free platinum from DNA, and hydrolysed (Fichtinger-Schepman et al., 1987) . The platinum content of DNA samples was assessed with a Spectra Zeeman 30 flameless atomic absorption spectrometer (Varian, Zug, Switzerland).
Cells and treatments Murine RIF-1 cells (provided by Dr R.F. Kallman; Stanford University, CA) and CHO cells were grown as monolayer cultures in Ham's FIO medium (Flow Laboratories, Irvine, UK) + 10% foetal calf serum (FCS; Sera-Lab, Sussex, UK) under standard conditions (37°C in a humidified 5% C02:95% air mixture). RIF-I cells were maintained involving alternating growth cycles in vivo and in vitro (Twentyman et al., 1980) . CHO cells were passaged weekly ten times before returning to a frozen stock. RIF-I and CHO cells were seeded into 60 x 15 mm dishes and treated [2] [3] [4] 
Immunocytochemical assay
The preparation of antiserum NKI-A59 against cisDDPmodified DNA has been described previously (Terheggen et al., 1988; Poirier et al., 1982) . NKI-A59 was used without purification at a dilution of 1: 1800. The immunostaining assay was carried as described (Terheggen et al., 1988) . Slides from the same experiment were stained simultaneously and all samples were stained in two independent tests. The density of the adduct-specific nuclear staining was measured at the single-cell level as previously reported (Terheggen et al., 1988) . The nuclear staining density, expressed in arbitrary units, represents the integrated optical density per nucleus. In each slide, the nuclear staining density of 15 randomly selected nuclei was measured (two slides per point). To compare adduct levels of cells which had been incubated with different drug doses, and/or during different incubation times, the nuclear staining density was expressed per JAM platinum per hour. The ratios of nuclear staining density JAM-i drug, used for the comparison of carboplatin vs cisDDP within a certain cell type, were obtained from the average values of all available ratios of nuclear staining density JAM' drug.
Statistics
Levels of significance were calculated using analysis of variance followed by Scheffe's test (Armitage, 1971) . The best fitting line between points and the correlation coefficient, based on a 95% confidence interval, were calculated by linear regression analysis.
Results
Binding of carboplatin and cisDDP to DNA in solution Carboplatin and cisDDP were reacted with calf thymus DNA for 0-72 h, free platinum was removed, and the platinum-DNA binding was measured by AAS. On a molar basis, 6.7 times more carboplatin than cisDDP was added to DNA. Figure 1 shows that the cisDDP-DNA binding reached a maximum between 6 and 24 h. In contrast, the reaction of carboplatin with DNA was still progressing after 24 h. The extent of carboplatin-DNA binding increased linearly with time (correlation coefficient >0.99, P <0.01). The reaction rate of cisDDP with DNA, measured between 0 and 6 h, was 35 times higher than the reaction rate of carboplatin with DNA, measured between 0-72 h. The maximum platinum-nucleotide ratios were 5.8 x 10-2 for cisDDP (mean from 20, 24 and 48 h) and 1.7 x 10-2 for carboplatin (at 72 h). Figure 3 ). The nuclear staining density in these buccal cells (calculated from the data in Figure 3 addition, differences in cell survival between carboplatin and cisDDP were paralleled by differences in DNA adduct levels ( Figure 7 ).
DNA adducts in cancer patients
To test whether the time course of adduct formation found in DNA in solution and in cultured cells also applies to human cells in situ, three patients were investigated from which buccal cells were collected at different times after cisplatin or carboplatin therapy. Highest nuclear staining densities were measured 10 h (patient A) or 14 h (patient B) after the end of the infusions with carboplatin ( Figure 8 ). in Figure 6 . For CHO cells, a 4-to 5-fold higher concentration of carboplatin was required to reach the same level of nuclear staining density as for RIF-I cells ( Figure 6 ). This is in contrast to the high ratio found for cells measured immediately after exposure (Figure 2 ). The correlation coefficients between the nuclear staining density (at 24 h) and the surviving fractions were 0.95 for RIF-I cells and 0.99 for CHO cells (P <0.01). When data from both cell lines were combined, a good correlation remained (Figure 7 ; correlation coefficient: 0.89; P < 0.01). Comparison with data from the cisDDP-treated groups showed that 41-48 times more moles carboplatin than cisDDP were required to induce the same level of nuclear staining density. Although a slightly different regression line was obtained when data for cisDDP were pooled with those for carboplatin, the coefficient of correlation between nuclear staining density and surviving fraction remained the same. This was true for each of the cell lines and for the combined data of both lines (Figure 7) . These experiments showed that carboplatin-DNA adduct levels in cultured cells correlated well with levels of cell killing. In 0.0011 \o between 6 and 10 h (patient A) and between 6 and 14 h (patient B). The observed maximum nuclear staining density imol' carboplatin in buccal cells from patient B was 1.4 times higher than in those from patient A. Although the number of time-points was relatively small for practical reasons, the results suggest some interpatient variation. The nuclear staining density in buccal cells from the cisDDPtreated patient C showed no significant incease (P >0.05) between 0 and 6 h after the end of the infusion (Figure 8) , showing that the level of cisDDP-DNA adducts was almost maximal immediately after infusion. From the data shown in Figure 8 it was calculated that a six times molar excess of carboplatin over cisDDP was required to achieve the same nuclear staining density in human buccal cells in situ.
Discussion
Carboplatin loses its cyclobutanedicarboxylato acid-ligand when it bifunctionally binds to DNA. The ultimate interaction products of carboplatin with DNA are, therefore probably chemically identical with those of cisDDP (Knox et al., 1986; Dijt, 1989) . This could explain why antiserum NKI-A59 raised against cisDDP-modified DNA, also recognises carboplatin-DNA adducts (Terheggen et al., 1988; com- pare also Reed et al., 1987) . The binding of carboplatin to DNA in solution was shown to proceed slower than that of cisDDP to DNA (Figure 1 ). It is known that only aquated derivatives of cisDDP and carboplatin can bind to DNA (Zwelling & Kohn, 1979) . Carboplatin's lower interaction rate with DNA can therefore be explained by its aquation rate, which can be up to 100 times lower than that of cisDDP (Cleare et al., 1978; Knox et al., 1986) . The relatively low aquation rate of carboplatin also explains why relatively high concentrations of this drug are required to obtain detectable adduct levels in cultured cells (Figures 2 and 3 ). An additional explanation for the relatively low adduct-specific immunostaining signals in the latter experiments follows from Figure 4 . This figure shows a substantial increase in the adduct-specific immunosignal of both CHO and RIF-1 cells after removal of carboplatin from the incubation medium. Although it cannot be excluded that these cells retain significant amounts of unreacted carboplatin after being washed twice, a more reasonable explanation seems to be the post-treatment conversion of already formed monofunctional carboplatin-DNA adducts into bidentate adducts (Knox et al., 1986) . Due to their bulky cyclobutanedicarboxylato acid group, the monovalent carboplatin-DNA adducts might not be recognised by antiserum NKI-A59, whereas the ultimate bidentate adducts, identical to bidentate cisDDP-DNA adducts, will be recognised. The relative contributions of these two factors, aquation rate and adduct recognition, to the low initial staining after carboplatin is yet unknown.
Our findings in cultured cells are in agreement with those reported in the literature. For example, carboplatin-DNA adduct levels in cultured Walker and V79 cells were found to be up to 40 times lower at a molar basis than cisDDP-DNA adduct levels (Knox et al., 1986) . The slow binding of carboplatin to DNA in solution (Figure 1 ) and, apparently, also to DNA in cultured cells (Figure 4) is consistent with published data on DNA-DNA cross-linking in cultured cells, which is maximal at 18 h post-treatment for carboplatin and between 6 and 12 h for cisDDP (Roberts & Friedlos, 1987) . These data are reminiscent of our present observation that the in situ rate of platinum-DNA binding in buccal cells from patients was markedly slower for carboplatin than for cisDDP (Figure 8 ). Other in vivo data (on rat kidneys) also suggest that carboplatin binds slower and to a much lower extent to cellular DNA than does cisDDP (Terheggen, 1989) . However, it is emphasised that these in vivo data cannot be compared directly with in vitro results (see below). In the present study it was shown that the immunostaining signal paralleled killing of cultured RIF-1 and CHO cells when both parameters were measured at 24 h after treatment (Figure 7) . In fact, a 4-fold difference between the two cell lines was found for both sensitivity to carboplatin and nuclear staining density. A similar correlation has previously been demonstrated for six cisDDP-treated mammalian cell lines (Terheggen et al., 1990a) . A comparison of Figure 2 with Figure 6 shows that the difference in nuclear staining density between RIF-1 and CHO cells was up to a factor 40 directly after treatment with carboplatin, and only a factor 4 to 5 at 24 h. This discrepancy suggests that the rate of net DNA adduction and/or the conversion rate of monovalent into bidentate adducts in one (or both) of these cells is not constant in time. Further investigations are needed to confirm the observed difference and to discriminate between the two possible explanations.
There was a marked difference between the in vitro and in vivo data on DNA modification by carboplatin. When highest levels of carboplatin-DNA binding were compared with the highest levels of cisDDP-DNA adducts, 41-48 times more moles carboplatin than cisDDP were required to reach a given level of platinum-DNA binding in cultured RIF-1 and CHO cells (see Results). This factor was only 6 to 17 when buccal cells from carboplatin-and cisDDP-treated cancer patients were compared (Figure 8 ; see Terheggen et al., 1988) and 4.3 ± 1.3 (mean ± s.e.) for buccal cells from 11 patients treated with carboplatin and cisDDP on different days (Terheggen et al., 1990b ; study in cooperation with F.M. Muggia, M.D., University of Southern California). An explanation for this in vitro/in vivo difference could be as follows. A lower binding level of carboplatin to DNA relative to cisDDP may partially be due to a decreased drug uptake. A prolonged drug exposure, as occurred in the patients, would allow more time for the uptake of carboplatin. The prolonged availability of free carboplatin in the blood plasma compared with that for free cisDDP would therefore contribute to the difference between in vivo and in vitro results.
A high correlation was shown between cell killing and the level of platinum-DNA binding, when measured 24 h after incubation with carboplatin (this paper) or directly after exposure to cisDDP (Terheggen et al., 1990a) . This suggests that, irrespective of the cell type or the drug, the adductspecific immunostaining signal is a quantitative indicator for in vitro cell kill, provided that time points of maximum DNA adduction are studied. The latter condition might be important especially for slowly reacting drugs like carboplatin. The cell kill/adduct correlation and the ability of the antiserum to detect carboplatin adducts at clinically relevant doses, coupled with the knowledge of the optimal measuring time, opens the possibility of immuno-staining tumour biopsy material for drug sensitivity.
